Skip to content
  • CAT
  • ESP
  • ENG
  • About us
  • Contact
El·lipse
  • instagram
  • twitter
  • flickr
  • linkdin
  • facebook
  • youtube
  • Research
  • Public engagement
  • Scientific life
  • Community
  • About us
  • Contact
  • instagram
  • twitter
  • flickr
  • linkdin
  • facebook
  • youtube
  • CAT
  • ESP
  • ENG

Clinical trials

15.12.2020

Public-private collaboration to develop a treatment for fragile X syndrome

Ivermectin was recently shown to inhibit the replication of SARS-CoV-2 in vitro at very high doses, but this effect has not yet been studied in vivo. The new study will investigate this question in a randomised trial. | Picture by ISGlobal.
21.05.2020

New study to assess the efficacy of ivermectin against COVID-19

So far, two recent studies suggest that hydroxychloroquine may be effective in reducing the viral load of SARS-CoV-2, although the results are inconclusive and further research is needed.
13.05.2020

New study to assess the efficacy of hydroxychloroquine in the prevention and treatment of COVID-19 during pregnancy

Patients who received redemsivir had a 31% faster recovery time than those who received placebo. There was a 4-day reduction in hospital stay. | Picture by Francisco Avia.
08.05.2020

The antiviral drug remdesivir reduces the time to recovery in COVID-19 patients

A study carried out by the IMIM confirms that the consumption of two biomolecules found in olive oil can be associated with improved endothelial function. | Picture by Pixabay from Pexels.
30.04.2020

Our blood vessels health could improve thanks to some biomolecules found in olive oil

Every 4 seconds a new case of Alzheimer's is diagnosed in the world. The PENSA Study aims to stop cognitive impairment in stages prior to the onset of dementia.
20.01.2020

PENSA Study: a commitment to primary prevention in Alzheimer’s

Drug development is a long and costly process. The clinical assays are the last part. Photo by freestocks.org on Unsplash
14.04.2008

Clinical trials: the long path to the development of new drugs

El·lipse is published by the PRBB Communications and Corporate Relations Area.

Dr Aiguader, 88, 08003 Barcelona, Spain

For any suggestions or collaborations please contact us at ellipse@prbb.org

  • Read past print editions
  • About El·lipse
  • About the PRBB
  • Legal disclaimer
  • instagram
  • twitter
  • flickr
  • linkdin
  • facebook
  • youtube
© 2021 El·lipse, PRBB
  • Home
  • News
  • Our picks
This website uses cookies that provide us with personal information, such as data associated with your browsing. If you click on I AGREE, both we and our Partners can install cookies or access non-sensitive information on your device in order to facilitate the reproduction of content, provide features on social networks, create profiles and compile statistics on traffic and usability in our website. You can get MORE INFORMATION by accessing our COOKIES POLICY. I agree More information
Privacy & Cookies Policy
Necessary Always Enabled

Subscribe to our mailing list
Want to be the first to know everything that goes on at the biggest biomedical research hub in Southern Europe? Subscribe to the el·lipse newsletter!

We will send you an email with the latest news.

See you soon!

You are subscribing to receive the newsletter in English. If you would like to receive it in Catalan or Spanish, please change the language settings in our web.

PRBB will use the information you provide on this form to be in touch with you and to provide updates. By clicking below to subscribe, you accept our privacy policy. You can unsubscribe at any time.